Physician profile
Dharampreet Singh
NPI 1396164190
$970.61
in general payments reported to CMS, 2019-2025
20 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.65 · 2022: $263 · 2023: $167 · 2024: $127 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $144.30 | 2025 | Pocket Eeg Device |
| Amgen INC. | $131.20 | 2025 | Repatha |
| Sk Life Science, INC. | $82.63 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $74.90 | 2022-2023 | |
| Lilly USA, LLC | $70.56 | 2022-2023 | Amyvid, Reyvow, Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $66.05 | 2022 | |
| Acadia Pharmaceuticals INC | $45.32 | 2024-2025 | Nuplazid |
| Ucb, INC. | $43.48 | 2024 | Zilbrysq, Rystiggo |
| Ge Healthcare | $43.45 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $42.67 | 2023-2024 | Soliris, Ultomiris |
| Sunovion Pharmaceuticals INC. | $41.01 | 2022 | |
| Abbvie INC. | $32.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.77 | 2022 | |
| Livanova USA, INC. | $24.91 | 2019 | |
| Biogen, INC. | $19.42 | 2025 | Leqembi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.89 | 2023 | |
| Impel Pharmaceuticals INC. | $16.60 | 2022 | |
| Genzyme Corporation | $14.74 | 2019 | |
| Argenx US, INC. | $13.82 | 2023 | Vyvgart |
| Neurelis, INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dharampreet Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.